Search | Page 15 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Benjamin L. Ebert, MD, PhD

    ... Recent work has elucidated the mechanism of action of lenalidomide , a drug that acts by modulating the function of an ...

    Bio last updated 03/11/2016 - 1:41pm.

  2. What are the treatments for MDS?

    ... of healthy bone marrow cells. These therapies include lenalidomide (Revlimid), decitaibine (Dacogen) and azacitidine ...

    FAQ last updated 03/15/2016 - 11:31pm.

  3. Therapies

    ... low- and high-risk patients with all sub-types of MDS. Lenalidomide (Revlimid®) is approved for transfusion-dependent MDS ...

    Page last updated 03/18/2016 - 11:26am.

  4. Amer Zeidan, M.D.

    ... and his colleagues confirmed the clinical benefits of lenalidomide and iron chelation therapy in patients with MDS at the ...

    Bio last updated 03/11/2016 - 1:41pm.

  5. FAQs

    ... bone marrow cells. These therapies currently include lenalidomide (Revlimid), decitabine (Dacogen) and azacitidine ... active treatments currently available. These include lenalidomide (Revlimid®) decitabine (Dacogen®) and ...

    Topic section last updated 03/02/2016 - 11:42am.

  6. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... of patients with MDS: immunomodulatory agents ( lenalidomide ), and hypomethylating therapy [HMT ( decitabine and ...

    Research Article last updated 05/12/2015 - 9:47am.

  7. What MDS Patients Should Know About Clinical Trials

    ... approved drugs available for people with MDS. These are lenalidomide (Revlimid®), azacitidine (Vidaza®), and ... MDS -- received either azacitidine alone, azacitidine and lenalidomide, or azacitidine combined with vorinostat.  I wrote this study ...

    Interview last updated 11/13/2015 - 11:12am.

  8. Nurse's Corner Summer 2015: Understanding the Etiology and Epidemiology of Myelodysplastic Syndromes

    ... Available options include erythroid stimulating agents, lenalidomide for patients with deletion 5 q MDS, hypomethylating agents and ...

    Page last updated 07/27/2015 - 12:04pm.

  9. Nursing Education Modules on MDS Disease Management and Patient Education

    ... Treatment options for low-risk MDS – observation, EPO, lenalidomide , immune suppression,       iron chelation Treatment ...

    Page last updated 04/27/2015 - 2:44pm.

  10. MDS Drug Information

    ... N eupogen lenalidomide R evlimid ...

    Page last updated 01/20/2015 - 4:46pm.